- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06438081
Comparison Between Propess and Cook Double-balloon Catheter for Cervical Priming
July 22, 2024 updated by: The University of Hong Kong
Comparison Between Propess (Dinoprostone Controlled Release Pessary) and Cook Double-balloon Catheter for Cervical Priming: a Randomized Controlled Trial
The investigators aimed to compare efficacy and safety of Propess versus Cooks double-balloon catheter for cervical ripening with an unfavorable cervix in term pregnancy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Previous studies focused on use of PGE2 instead of Propess, which is a preparation of PGE2 packaged in a hydrogel polymer matrix and release 10mg dinoprostone at 0.3mg per hour for 24 hours.
Compared with PGE2, Propess can achieve a shorter induction-to-birth interval, a higher rate of vaginal delivery within 24 hours, and a smaller number of vaginal examinations during delivery.
However local studies comparing the efficacy and satisfaction of cervical priming between Cook double-balloon catheter and Propess were lacking.
The investigators aimed to compare efficacy and safety of Propess versus Cooks double-balloon catheter for cervical ripening with an unfavorable cervix in term pregnancy.
Study Type
Interventional
Enrollment (Estimated)
28
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yin Fong Leung, MBBS
- Phone Number: 852 22554517
- Email: lyf971@hku.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Queen Mary Hospital
-
Contact:
- Yin Fong Leung, MBBS
- Phone Number: (852)-2255-4517
- Email: yin_fong18@yahoo.com.hk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Viable singleton pregnancy
- Cephalic presentation
- Bishop score <7
- At term (>=37+0 weeks of gestation)
- Nulliparous women
Exclusion Criteria:
- Gestation <37weeks
- Multiple pregnancy
- Bishop score <7
- Malpresentation
- Contraindication to vaginal delivery
- Previous Caesarean section
- History of myomectomy
- Maternal fever
- Suspected infection
- Abnormal fetal heart-rate patterns
- Rupture of membranes
- Intrauterine growth restriction
- Not fit for giving consent
- Allergic to Propess or PGE2
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Cook double-balloon catheter
Participant is placed in lithotomy position, then to clean vulval and vaginal area, followed by inserting vaginal speculum.
Cook double-balloon catheter will be inserted under standard technique.
Doctor or midwife guide the cervical ripening balloon with stylet to pass through the cervix.
Uterine balloon should be place above level of internal os, then to remove the stylet before further advancing the catheter.
Cook double-balloon catheter is further advancing through the cervix until both balloons entered cervical canal.
Uterine and vaginal balloons are both inflated with up to 80ml normal saline according to manufacturer recommendation.
Maximal duration of balloon placement will be 12 hours.
If cervix remains unfavorable after Cook double-catheter balloons, she will be given another Cook double-catheter balloons priming the next day.
If cervix remains unfavourable after two balloon priming, elective Caesarean section will be advised.
|
To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
|
|
Placebo Comparator: Propess
Participant will be firstly confirmed reactive tracing and without regular contraction by non-stress test for 20mins.
Propess will be checked its integrity and applied with lubricating jelly before insertion.
Propess is inserted to the posterior vaginal fornix.
Woman should inform medical staff if they have leaking sensation.
After insertion, woman will be advised to lie down and perform non-stress test for 2 hours.
Propess will be removed after 24 hours post insertion.
Cervical assessment is performed the next day after removal of Propess.
Patient with favourable cervix, i.e.
Bishop score >= 7, will start artificial rupture of membrane and syntocinon infusion.
Patient with unfavorable cervix, i.e.
Bishop score <7 is arranged another day of priming by PGE2.
If the cervix remains unfavorable after 2 days of pharmacological priming, women will be given a rest day or continued priming by Cook double-balloon catheter.
|
To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Priming to delivery interval
Time Frame: 1 year
|
Time for priming (device placement) to delivery interval
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vaginal delivery within 24 hours after priming
Time Frame: 1 year
|
delivery within 24 hours
|
1 year
|
|
Caesarean section rate
Time Frame: 1 year
|
need of resort to Caesarean section and the corresponding indication
|
1 year
|
|
Vaginal delivery rate
Time Frame: 1 year
|
included instrumental delivery, e.g.
vacuum extraction, forcep delivery
|
1 year
|
|
Priming to induction interval
Time Frame: 1 year
|
Time from priming to induction
|
1 year
|
|
Need of induction with oxytocin
Time Frame: 1 year
|
Chance of going into spontaneous labor after priming
|
1 year
|
|
Amount of oxytocin use
Time Frame: 1 year
|
calculate the amount of oxytocin use
|
1 year
|
|
Malpresentation after priming
Time Frame: 1 year
|
to confirm if cephalic presentation before start of induction
|
1 year
|
|
Failed induction rate
Time Frame: 1 year
|
defined as cervix failed to dilate to more than 3cm after 12 hours use of oxytocin
|
1 year
|
|
Uterine hyperstimulation
Time Frame: 1 year
|
defined by a single contraction lasting for more than 2 minutes or more than 5 contractions in 10 minutes for 30 minutes
|
1 year
|
|
Suspected intrauterine infection rate
Time Frame: 1 year
|
infection rate that require antibiotics treatment
|
1 year
|
|
Primary postpartum haemorrhage
Time Frame: 1 year
|
Blood loss >500ml within 24 hours of delivery
|
1 year
|
|
Length of hospital stay
Time Frame: 1 year
|
calculate length of hospital stay after delivery
|
1 year
|
|
Maternal satisfaction with the procedure
Time Frame: 1 year
|
on a visual analogue scale to rate maternal satisfaction of from 1 to 5, 5 is better, 1 is worse
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yin Fong Leung, MBBS, The University of Hong Kong
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
May 26, 2024
First Submitted That Met QC Criteria
May 26, 2024
First Posted (Actual)
May 31, 2024
Study Record Updates
Last Update Posted (Actual)
July 24, 2024
Last Update Submitted That Met QC Criteria
July 22, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW 24-172
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.